980,068 Shares in Teladoc Health, Inc. $TDOC Bought by Jupiter Asset Management Ltd.

Jupiter Asset Management Ltd. bought a new position in shares of Teladoc Health, Inc. (NYSE:TDOC) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 980,068 shares of the health services provider’s stock, valued at approximately $7,576,000. Jupiter Asset Management Ltd. owned about 0.55% of Teladoc Health as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of TDOC. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Teladoc Health by 2.8% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 193,714 shares of the health services provider’s stock valued at $1,542,000 after buying an additional 5,235 shares during the period. NewEdge Advisors LLC boosted its holdings in Teladoc Health by 1,278.7% in the first quarter. NewEdge Advisors LLC now owns 11,305 shares of the health services provider’s stock valued at $90,000 after acquiring an additional 10,485 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in Teladoc Health by 5.7% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 447,992 shares of the health services provider’s stock valued at $3,566,000 after purchasing an additional 24,124 shares during the period. Acadian Asset Management LLC acquired a new stake in Teladoc Health during the 1st quarter valued at approximately $615,000. Finally, Caitong International Asset Management Co. Ltd raised its holdings in Teladoc Health by 8,192.0% during the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 8,292 shares of the health services provider’s stock worth $72,000 after purchasing an additional 8,192 shares during the last quarter. 76.82% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other Teladoc Health news, CEO Charles Divita III sold 17,138 shares of Teladoc Health stock in a transaction that occurred on Thursday, December 11th. The shares were sold at an average price of $7.63, for a total transaction of $130,762.94. Following the transaction, the chief executive officer owned 201,036 shares of the company’s stock, valued at $1,533,904.68. The trade was a 7.86% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Adam C. Vandervoort sold 5,720 shares of Teladoc Health stock in a transaction on Tuesday, December 2nd. The shares were sold at an average price of $7.49, for a total transaction of $42,842.80. Following the completion of the sale, the insider owned 80,732 shares in the company, valued at approximately $604,682.68. This represents a 6.62% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 33,288 shares of company stock worth $251,684 in the last quarter. 0.58% of the stock is currently owned by insiders.

Teladoc Health Price Performance

Shares of NYSE:TDOC opened at $4.75 on Friday. The company has a debt-to-equity ratio of 0.71, a current ratio of 2.70 and a quick ratio of 2.60. The company has a market capitalization of $842.10 million, a PE ratio of -3.71 and a beta of 2.12. Teladoc Health, Inc. has a 1-year low of $4.40 and a 1-year high of $12.69. The business has a fifty day moving average price of $6.23 and a 200-day moving average price of $7.27.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the stock. Bank of America reduced their price objective on shares of Teladoc Health from $9.00 to $8.00 and set a “neutral” rating on the stock in a research note on Tuesday, November 25th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Teladoc Health in a research report on Monday, December 29th. Zacks Research cut shares of Teladoc Health from a “strong-buy” rating to a “hold” rating in a report on Monday, November 10th. BMO Capital Markets initiated coverage on Teladoc Health in a research note on Thursday, November 13th. They issued a “market perform” rating and a $8.00 price objective on the stock. Finally, Barclays initiated coverage on shares of Teladoc Health in a research note on Tuesday, December 9th. They set an “equal weight” rating and a $8.50 price target on the stock. Three investment analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $9.12.

About Teladoc Health

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.